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Abstract
Introduction—Lung cancer incidence is higher among NH blacks compared with NH white and 
Hispanic populations in the U.S. However, national cancer estimates may not always reflect the 
cancer burden in terms of disparities and incidence in small geographic areas, especially urban-
rural disparities. Moreover, there is a gap in the literature regarding rural-urban disparities in terms 
of cancer histology.
Methods—Using population-based cancer registry data—Surveillance, Epidemiology and End 
Results (SEER) and National Program of Cancer Registries (NPCR)—we present age-adjusted 
histologic rates and trends by race/ethnicity, and residential county location at the time of first 
cancer diagnosis. Rate ratios were calculated to examine racial/ethnic differences in rates. Annual 
percent change (APC) was calculated to measure changes in rates over time.
Results—We find that declines in squamous cell carcinoma (SCC) are occurring fastest in 
metropolitan counties, while rates of adenocarcinoma increased fastest in counties nonadjacent to 
metropolitan areas. Further, while NH black men have increased lung cancer incidence compared 
with NH white and Hispanic men in all geographic locations, we find that the degree of the 
disparity increases with increasing rurality of residence. Finally, we report that among women 
diagnosed at less than 55 years of age, the incidence of SCC and adenocarcinoma was higher for 
NH blacks compared with NH whites.
Conclusions—Our results highlight disparities among NH blacks in non-adjacent rural areas. 
These findings may have significant impact for the implementation of smoking cessation and lung 
cancer screening programs.
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Introduction
Although cigarette smoking has significantly decreased over the past few decades, 
disparities in tobacco use and lung cancer incidence remain across race, ethnicity, education, 
and socioeconomic status (SES) in the United States (US)1–4. The main types of lung cancer 
include small cell and non-small cell (adenocarcinoma, squamous cell carcinoma, and large 
cell carcinoma). Approximately 80–85% of lung cancers are non-small cell, compared with 
10–15% of small cell cases. Most lung cancers are due to smoking; however, the strength of 
association varies by histological subtype5. Evidence suggests cigarette smoking is more 
strongly associated with small cell and squamous cell carcinomas and less associated with 
adenocarcinoma and large call carcinoma6–8. Public health campaigns around the negative 
health consequences of smoking initiated a decline in smoking prevalence and a decrease in 
lung cancer incidence towards the end of the last century. Squamous cell and small cell lung 
cancers declined, but the adenocarcinoma subtype increased. While some of these 
histological changes are attributed to the global decline in smoking prevalence,4 changes in 
the design and composition of cigarettes— both of which modified inhalation and patterns 
of use—are also attributable causes4,9–11. Racial and ethnic differences in smoking 
behaviors and lung carcinogenesis12 suggest that some racial/ethnic groups are more 
susceptible to lung cancer2. For instance, despite lower smoking prevalence rates2, later age 
of smoking initiation13–15, and lower number of cigarettes smoked per day13, non-Hispanic 
(NH) blacks are disproportionately affected by lung cancer compared with NH 
whites13,16–19. Furthermore, among Hispanic populations, the incidence of lung cancer is 
lower than NH whites20—a trend that is also observed among first generation U.S. 
Hispanics21—while the prevalence of smoking in aggregate is approximately 40–50% lower 
compared with NH whites, though it is worth noting that there are marked differences in 
smoking patterns according to country of origin13,20. Collectively, cigarette smoking 
patterns appear to contribute to, but not fully explain racial/ethnic disparities in lung cancer 
incidence22–26. Thus, some aspects of racial/ethnic disparities in lung cancer incidence may 
be associated with modifiable exposures or other unmeasured facets of tobacco use27.
Geographical residence—and associated environmental exposures such as smoking, radon, 
pollution and other unknown factors—is one potential co-factor that mediates racial/ethnic 
disparities in lung cancer incidence28. Smoking rates and unhealthy behaviors, for example, 
are higher in rural areas29–31. A recent comprehensive description of histologic lung cancer 
incidence rates and trends in the United States demonstrated that lung cancer rates overall 
are highest in the South, while lung adenocarcinoma rates are highest in the Northeast 
region3,19. Moreover, recent work has suggested that higher altitude is associated with 
reduced incidence of lung cancer32–34. Few studies have examined differences in lung 
cancer incidence using small or well-defined geographic regions. These studies are 
important, as they may help to identify regions with patients at high risk for lung cancer that 
can be targeted for outreach and implementation of low dose CT (LDCT) screening. Efforts 
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are also needed to reduce disparities in rural and urban lung cancer rates, however, to do so, 
one first needs to identify and characterize these disparities. In this study, we examined 
county-level lung cancer incidence rates by histology with an emphasis on racial/ethnic and 
geographical differences.
Materials and Methods
Data sources
Incident lung and bronchus cancer cases diagnosed between 2004 and 2013 were obtained 
from the Centers for Disease Control and Prevention National Programs of Cancer 
Registries (NPCR), and the National Cancer Institute’s Surveillance, Epidemiology, and End 
Results (SEER) registries. Together these two registries provide cancer incidence data for 
100% of the U.S population without duplication of individual registries. NPCR and SEER 
are required to have <2 unresolved duplicates per 1000 cases in order to meet USCS 
publication. The Registry Plus™ Link Plus system is used to detect duplicate records. All 
registries that met the United States Caner Statistics data quality standards were included. 
Minnesota and Kansas were excluded from the study due to missing county-level data, and 
Nevada was excluded because state-wide data did not meet high-quality standards for all 
study years, resulting in 96.5% coverage of the U.S. population.
Since the influence of cigarette smoke on the risk of lung cancer histological subtypes is not 
equal8, we examined incidence rates and trends for all major histologic lung cancer 
subtypes. Lung cancer histology groups were defined using International Classification of 
Diseases for Oncology version 3 (ICD-0-3): Small cell (8002–8005, 8041–8045); Non-small 
cell (8046); Squamous (8052, 8070–8076, 8078, 8083–8084, 8094, 8120, 8123); 
Adenocarcinoma (8050, 8140–8141, 8144, 8201, 8250–8255, 8260, 8290, 8310, 8320, 8323, 
8333, 8470, 8480, 8481, 8490, 8507, 8550, 8570, 8572, 8574, 8576); Large cell (8012–
8014, 8021, 8082); Carcinoma, NOS (8000, 8001, 8010, 8020, 8230); Other specified types 
(8022, 8030, 8031–8033, 8200, 8240, 8241, 8244–8246, 8249,8430, 8560, 8562, 8575); 
Sarcoma (8800–8805, 8810, 8811, 8815, 8830, 8890, 8900, 8940, 9040, 9041, 9043, 9120, 
9133, 9220, 9231, 9473, 9540) (Supplementary Table 1). Cases were restricted to non-
Hispanic (NH) white, NH black and Hispanic adults (18 years and older), with Hispanic 
ethnicity being mutually exclusive from race categories. Cases verified by autopsy only or 
death certificate only and not microscopically confirmed were excluded from the study.
Using state-county American National Standards Institute codes, also referred to as Federal 
Information Processing Standards (FIPs) codes, incidence data were assigned 2003 county-
level Rural-Urban Continuum Codes (RUCC) based on the county of residence at the time of 
first diagnosis. RUCC is a county-level assessment of rurality and urbanization where codes 
range from 1–9—the system was developed by the United States Department of 
Agriculture35. For metropolitan/non-metropolitan variation analysis, counties were 
categorized into metropolitan (RUCC-M; 1–3), adjacent to metropolitan (RUCC-A; 4, 6, 8), 
and non-adjacent to metropolitan (RUCC-R; 5, 7, 9)28. RUCC 1–3 correspond to counties in 
metropolitan areas of 250,000 or more; codes 4, 6 and 8 correspond to counties in urban and 
rural counties adjacent to metropolitan areas; codes 5, 7, and 9 correspond to urban and rural 
counties not adjacent to a metropolitan area.
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Statistical analysis
Age-adjusted incidence rates were calculated for each year and by histologic subtype, sex, 
race/ethnicity, and county residence (rural-urban status). Racial/ethnic incidence rate ratios 
were calculated using NH white age-adjusted rate as the referent group compared with rates 
for NH black and Hispanic adults. Rates are calculated per 100,000 persons and 95% 
confidence intervals (CIs) were calculated for rates and rate ratios (4). Rate ratios were 
calculated to examine differences in rates between race/ethnic groups. Annual percent 
change (APC) was calculated to measure rate trends over time. Differences between racial/
ethnic groups within each region were considered significant at P < 0.05. All data analyses 
were performed using SEER*Stat software version 8.2.1. The Tiwari method was used to 
calculate confidence intervals for rate ratios and rates36.
Results
A total of 1,491,055 NH whites, 190,060 NH blacks, and 70,613 Hispanics were diagnosed 
with lung cancer between 2004 and 2013. The majority of cases resided in metropolitan 
counties at the time of first cancer diagnosis (Table 1). Rates for NH black and NH white 
men living in metropolitan counties are similar (61.1 & 60.2 per 100, 00, respectively), 
whereas rates for NH white living in counties adjacent to metropolitan counties are higher 
than NH blacks (63.3 and 60.5 per 100,000, respectively) and rates for NH black living in 
counties not adjacent to metropolitan counties are higher that NH white (61.2 and 60.9 per 
100,000, respectively). The overall rates of lung cancer among adults age 45–54 and 55–64 
years were higher for NH blacks (54.4 and 154.0 per 100,000, respectively) and lower for 
Hispanics (15.5 and 55.3 per 100,000, respectively), compared with NH whites (43.4 and 
131.3 per 100,000, respectively) (Table 1). Adenocarcinoma had the highest incidence 
followed by squamous cell carcinomas among all racial/ethnic groups. Incidence of late 
stage disease was higher among NH blacks (33.4 per 100,000), compared with NH white 
(30.8 per 100,000) and Hispanic adults (15.9 per 100,000).
As shown in Table 2, among U.S. adult males, <55 years of age, NH blacks have the highest 
incidence rates for squamous cell (2.3 per 100,000), adenocarcinoma (5.3 per 100,000), and 
large cell (0.5 per 100,000) lung cancers. Historically, NH black women have a lower 
incidence of lung cancer, compared with NH white women10,37,38. However, our analysis 
demonstrates that among women <55 years of age, squamous cell (rate ratio: 1.19), 
adenocarcinoma (rate ratio: 1.10) and large cell carcinoma (rate ratio: 1.15) incidence rates 
are significantly higher, compared with NH white women (Table 2). The incidence for small 
cell cancers is significantly lower for Hispanic (rate ratio: 0.45) and NH black (rate ratio: 
0.80) men compared with NH white men (Table 2). We further analyzed these data by 
looking at APCs during the period 2004 to 2013. Interestingly, our study finds that for most 
age groups (55+) the APC of lung adenocarcinoma is higher among NH black women than 
NH white women. Similar observations were made among men (Table 2).
Table 3 shows sex-specific histologic lung cancer incidence rates and trends by regional 
location and race. Rates of squamous cell among men were significantly higher in adjacent 
metropolitan (rate ratio: 1.25) and non-adjacent (rate ratio: 1.19) counties compared with 
rates for men living in metropolitan counties. Similar observations were observed for women 
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(Table 3). We noted that the incidence racial disparity persisted among men regardless of 
residential location. However, we observed that degree of disparity in incidence of lung 
squamous cell carcinoma between NH black men, and NH white men, increased linearly 
with decreasing proximity to metropolitan counties, rising from 24% to 29% to 45% in 
metropolitan, adjacent metropolitan and non-adjacent metropolitan locations, respectively.
We observed declining rate trends for small cell and squamous cell lung cancer in both men 
and women, with greater significant rate declines occurring in men and women living 
metropolitan counties (Table 3). For small cell lung cancers, there is evidence that greater 
declines occur among NH Black men and women living in metropolitan counties (APC for 
men −3.6%, APC for women −2.3%).
The incidence of lung adenocarcinoma in metropolitan counties and counties not adjacent to 
metropolitan counties were significantly higher among NH black men compared with NH 
white men (Table 3). The degree of disparity between NH white and NH black men with 
lung adenocarcinoma was greater with increasing rurality of county, with rates increasing 
more rapidly among NH black men living in metropolitan counties (APC = 2.0%) and 
counties not adjacent to metropolitan counties (APC = 4.6%) (Table 3). Although lung 
adenocarcinoma rates for NH black women are significantly lower than NH white women 
for all geographic locations, rates increases are greater among NH black women (Table 3).
The incidence of large cell lung cancer was significantly higher in non-metropolitan counties 
compared to metropolitan counties, for both men and women. Compared to NH white men 
rates for NH black men in metropolitan counties and counties adjacent to metropolitan 
counties were significantly higher (rate ratio: 1.22 and 1.33 per 100,000, respectively) and 
significantly lower among Hispanics in all regional locations (rate ratio: 0.47, 0.53, and 0.47 
per 100,000, respectively). Compared to NH white women, large cell lung cancer incidence 
was slightly lower among NH black (rate ratio:0.93) and Hispanic women (rate ratio: 0.35), 
in metropolitan counties. The data also support a declining incidence of large cell lung 
cancer overall (Table 3).
Small cell lung cancer is the one histological subtype where the incidence is lower in NH 
blacks and Hispanic adults compared with NH whites (Table 3). Lower rates among NH 
black and Hispanic adults remain consistent across regional locations. Incidence rates 
significantly decreased among adults living in metropolitan counties, and among women 
living in counties not adjacent to metropolitan areas (Table 3).
Discussion
Recent comprehensive studies of histologic lung cancer incidence rates and trends in the 
U.S. demonstrated that rates vary by both race/ethnicity and geographic location3,1939,40. 
However, these studies addressed geographic variance using topographical analyses at the 
census19 or state-wide40 level. This study uses national data to provide up-to-date racial/
ethnic rates and trends of histologic type of lung cancers by U.S. residential county.
In this study, our main research question was whether there was geographic variance in 
racial disparities at the county level. Our results show that the higher incidence of lung 
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cancer in NH black men compared with NH white men is observed in metropolitan and non-
adjacent counties, but that the degree of disparity increases the further counties are situated 
from metropolitan areas. We also observed significantly higher rates of large cell lung cancer 
incidence in NH black women living in counties adjacent to metropolitan counties compared 
to NH white counterparts. To our knowledge, this is the first time that these trends have been 
reported.
Studies show rural-urban differences in smoking behaviors31, where the smoking prevalence 
is higher in rural counties. Thus, it is possible that smoking contributes to the increased 
disparity in non-adjacent counties among NH black men. Studies that directly compare 
racial differences in smoking in rural areas are rare to our knowledge. One study, in 
adolescents, shows that cigarette smoking is higher among NH whites compared with NH 
blacks41. However, given the later age at which NH blacks initiate smoking, this is not 
necessarily surprising15. We are not aware of studies among adults that break down these 
observations by race/ethnicity and gender. In addition, smoking is a very complex exposure 
to capture. In addition to status (i.e., current, former and never), dose (cigarettes per day, 
CPD), duration, age at initiation, time to first cigarette and daily versus non-daily use are 
key aspects of smoking relevant to its relationship with cancer. Moreover, depth of 
inhalation, smoking efficiency, type of tobacco (filtered, menthol, smokeless, etc), are all 
factors that likely contribute to the complex relationship between smoking, lung cancer and 
racial disparities.
While several exposures have been linked with lung cancer, the effect size for smoking ranks 
the highest by far. Other environmental and lifestyle exposures could contribute to this 
disparity, including radon exposure, ambient air quality, and exposure to asbestos, pesticides, 
diesel, and additional pollutants. Indeed, NH blacks are disproportionately employed in jobs 
where they are exposed to these factors42,43 and often live in areas with higher sources of 
pollution44–51. Data are sparse regarding the relationship between household radon levels 
with race and geographic location, thus it is difficult to evaluate radon’s potential 
contribution to lung cancer disparities in this context52,53. Interestingly, studies where the 
association between exposure to carcinogens and lung cancer risk have been examined in 
different racial/ethnic groups show that the effect of the relationship was stronger in NH 
blacks, compared with NH whites and stronger in rural counties54.
We also examined how trends in lung cancer incidence are changing in the context of 
residential location. In accordance with the general literature and the most recent annual 
report55, we observe a decrease in squamous cell carcinoma, large cell carcinoma and small 
cell carcinoma in both men and women. However, our analysis looked at these trends in 
greater detail and found that the greatest declines are generally observed in metropolitan 
counties, something that has not been described previously to the best of our knowledge. 
Interestingly, the one exception to this declining trend is adenocarcinoma, which continues 
to rise4. Our data show that the increases, at least in recent years, appear to be occurring 
more so in non-adjacent counties in both men and women, with some of the largest increases 
also observed among NH black men. This observation is consistent with recent work using 
SEER 18 showing that cancer incidence is highest in rural counties56. Our work extends this 
by showing how rural and urban differences, defined by metropolitan county residence and 
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non-adjacent to metropolitan country residence, are affected by sex, histological and racial/
ethnic factors.
Increases in adenocarcinoma have been documented for several decades4,10,38,55, though 
whether there is an absolute increase in lung adenocarcinoma among never smokers remains 
controversial57–59. Many factors contributed to these changes, including changes in smoking 
prevalence, and changes in cigarette design and composition4,60–62. For example, cigarette 
ventilation, which modifies the delivery of carcinogenic constituents63, gained market share 
due to the perception that it made smoking safer. It didn’t. Rather, the ventilation of 
cigarettes changed the histological profiles of lung cancer. Possible explanations for the 
recent increases in lung adenocarcinoma include air pollution in the form of nitric 
oxides64,65 and industrialization66,67.
One other key racial difference in smoking habits is the type of cigarette used; NH blacks 
preferentially use mentholated cigarettes. Due to its “cooling” properties, menthol counters 
the irritant effect of toxicants found in tobacco68,69. Mentholation can affect smoking 
behavior68,70–75. Indeed some studies have linked mentholated tobacco with reduced odds of 
quitting73–75, which could contribute to the lower quit rates among AAs overall68. However, 
studies do not support the hypothesis that menthol cigarettes are associated with a greater 
risk of lung cancer compared with other tobacco types24–26,76.
In our study we tried to address whether changes in the histological classification of lung 
cancer could drive the increases in adenocarcinoma that we observed (Supplementary Table 
2). Recent years have seen a trend whereby nonspecific classification of lung cancer is 
avoided and more cases are designated as either adenocarcinoma and squamous cell 
carcinoma or other specific subtypes61. As mentioned, we observed that increases in 
adenocarcinoma were occurring mostly in adjacent and non-adjacent counties. If this was 
driven primarily by differences in classification of other histological subtypes—such as non-
small cell lung cancer (NSCLC), carcinoma not otherwise specified (NOS) and sarcoma—
one might expect to see greater decreases in the same geographic areas for those subtypes. 
However, for both carcinoma, NOS and NSCLC, while decreases are observed for both, the 
greatest decreases are observed in metropolitan counties (Supplementary Table 2). Similarly, 
the slight increases in adenocarcinoma in non-adjacent counties in men do not seem to be 
driven by better classification of carcinoma NOS or NSCLC (Supplementary Table 2). 
Interestingly, a recent paper by Patel and colleagues that analyzed lung cancer incidence 
trends in California over a 28 year period found that increases in lung adenocarcinoma 
among women were more pronounced in areas of low neighborhood socioeconomic status. 
These data would appear to be congruent with our data regarding lung adenocarcinoma 
increases non-adjacent counties77.
Our analysis also highlighted a disparity among young NH black women, compared with 
NH white women for squamous cell, adenocarcinoma and large cell lung cancers. Overall, 
NH black women had lower rates of adenocarcinoma, compared with NH white women. 
However, as noted earlier, this trend was reversed among women diagnosed with lung cancer 
<55 years of age. While this observation is not often discussed, previous studies have also 
highlighted a similar trend78–80. Moreover, a meta-analysis of never smokers (without age 
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stratification) also described increased incidence of lung cancer in NH black women 
compared with NH white women. One possible explanation for this relates to the recent 
apparent rise of lung cancer in never smokers81. Adenocarcinoma mostly occurs in never 
smokers and never smokers tend to be diagnosed at an early age58,82. However, this is just 
speculative and will need to be addressed in future studies. We also noted that the recent 
increases in adenocarcinoma among women are primarily occurring among NH blacks.
Similar to previous work, we observed lower lung cancer incidence, of every histological 
subtype, in Hispanics compared with NH black and white adults. These decreases in 
incidence did not appear to correlate with any specific geographic location. There is perhaps 
one exception in that the incidence of carcinoma NOS seemed to be higher in Hispanics, 
compared with NH whites. However, as the trend was not statistically significant, it is not 
possible to draw conclusions on what it might mean. Moreover, our data confirmed 
decreasing incidence of SCC in Hispanic men. While rates of squamous cell lung cancer 
appeared to be rising in women, the increases were not statistically significant. Reasons for 
this observation are not clear, but deserve further follow up. Of note, the greatest changes in 
the incidence of carcinoma NOS, NSCLC and other histological types of lung cancer 
occurred among Hispanics (Supplementary Table 2).
In 2015, LDCT screening was approved for CMS reimbursement. However, studies show 
that the screening uptake remains low, is currently lower among NH blacks and that targeted 
intervention strategies may be needed, both to maximize the potential to reduce lung cancer 
mortality overall and to possibly reduce racial disparities and rural-urban disparities in lung 
cancer outcome83. Importantly, our data confirm the previously observed trend that lung 
cancer is diagnosed at a later stage in NH blacks, something that contributes to disparities in 
outcomes. To ensure that disparities in stage at presentation do not widen in the era of 
LDCT84, dedicated efforts should be made to ensure that the most vulnerable populations 
have access to screening. Our data show that disparities are highest in non-adjacent counties 
and that some of the main increases in lung adenocarcinoma are also occurring in these 
areas. As such, these counties could be targets for more intensive interventions. However, to 
plan for both smoking cessation and LDCT intervention programs, more extensive analyses 
are needed on smoking prevalence by race, gender and urban–rural residence.
Our study has several strengths and limitations. We are the first to assess lung cancer 
disparities at a small geographic county level across the main histological subtypes. 
Secondly, our study covers over 96% of the U.S. population. This was possible as using 
NPCR-SEER data meant that we had greater population coverage than SEER alone. 
However, limitations include the possibility that the classification of rural populations into a 
single category is not optimal. By pooling counties together, we did not have the ability to 
define discrete pockets of disparity—if any indeed exist. As noted28, the classification of 
‘rural’ or ‘non-adjacent’ counties is not in itself, a homogenous classification. Also, county-
level associations do not reflect individual exposures. In addition, we cannot rule out the 
potential misclassification of Hispanic ethnicity (60), which could bias some of our findings. 
It is also possible that a delay in cancer reporting may result in underestimation of incidence 
(61), but since we used data from multiple years, our estimated cases are likely to be only a 
slight underestimation. Moreover, important risk factor data, such as smoking behaviors, are 
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not available within our cancer registry data set and therefore we were unable to directly 
examine the influence of these risk factors on our findings.
Using nationwide county-level data, our study demonstrates significant county-level 
differences in lung cancer rates and trends in NH white, NH black and Hispanic U.S. adults. 
We observed significant and increasing disparities in adenocarcinoma in non-adjacent 
counties and among NH black men and women, suggesting the need for further study of this 
population. It is possible that factors that confound the increase of adenocarcinoma in the 
general population could also be responsible for the rural trends we observe4,10,38,55,60–62. 
The variations observed by race and geography, along with the continuing rise of 
adenocarcinoma, point to potential knowledge gaps in our understanding of all the risk 
factors—behavioral, social and environmental—that drive lung cancer incidence in addition 
to, or in cooperation with, smoking in the United States. It will be important to implement 
primary prevention (smoking prevention and cessation and reduced exposure to other lung 
carcinogens) and lung cancer screening strategies that target specific population groups. 
Evidence already suggests both racial and urban-rural disparities in the uptake of screening 
programs for other cancer types85–87. Therefore, as the practice of low dose computed 
tomography screening becomes more widespread across the United States, it will also be 
important to continue monitoring such trends in lung cancer incidence across racial and 
geographic groups84 by age so that appropriate resources can be put in place to reduce 
disparities in lung cancer incidence and death.
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